Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>
Kim A. Reiss(University of Pennsylvania), Susan M. Domchek(University City Science Center), Natallia Izgur(University of Pennsylvania), Stacy Cowden(University of Pennsylvania), Gregory L. Beatty(Cancer Research Institute), Traci Southwell(University of Pennsylvania), Thomas B. Karasic(Hospital of the University of Pennsylvania), Zain M. Hannan(University of Pennsylvania), Robert H. Vonderheide(University of Pennsylvania), Mark H. O’Hara(University of Pennsylvania), Rosemarie Mick(University of Pennsylvania), Max M. Wattenberg(Washington University in St. Louis), Charles Schneider(University of Pennsylvania), Ursina Teitelbaum(University of Pennsylvania), Katherine L. Nathanson(Translational Therapeutics (United States)), Rashmi Tondon(University of Pennsylvania), Janae Romeo(University of Pennsylvania)
Cited by 238
Related Papers
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Network modeling links breast cancer susceptibility and centrosome dysfunction
|Nature Genetics|2007|634